prostat
cancer
pc
repres
second
caus
cancer
mortal
men
mainli
patient
relaps
castrationresist
prostat
cancer
crpc
two
year
androgen
ablat
final
treatment
option
chemotherapi
docetaxel
median
overal
surviv
twothre
month
recent
cabazytaxel
abirateron
approv
chemo
endocrinetherapi
agent
overal
surviv
around
month
actual
therapeut
strategi
delay
prevent
emerg
castrationrefractori
phenotyp
advanc
pc
involv
target
gene
activ
androgen
withdraw
review
heat
shock
protein
involv
pleiotrop
cell
function
review
highli
overexpress
gene
crpc
aberr
express
associ
tumor
growth
resist
hormon
therapi
cell
death
inhibit
poor
prognosi
silenc
express
use
antisens
oligonucleotid
aso
small
interf
rna
sirna
increas
apoptot
rate
induc
tumor
regress
enhanc
hormon
chemotherapi
pc
despit
excel
result
observ
relev
clinic
trial
http
wwwoncogenexca
function
role
stressinduc
castrat
chemotherapyinduc
cell
death
remain
poorli
defin
purpos
work
elucid
pathway
lead
action
crpc
find
new
specif
therapeut
target
treatment
strategi
crpc
would
limit
toxic
normal
tissu
use
twohybrid
experi
previous
found
play
major
role
protein
translat
initi
process
data
led
us
investig
protein
synthesi
initi
pathway
prerequisit
cell
growth
prolifer
thu
northern
western
blot
analysi
found
downregul
decreas
express
protein
level
without
affect
mrna
content
cytoprotect
afford
overexpress
attenu
knockdown
use
specif
sirna
coimmunoprecipit
coimmunofluoresc
experi
confirm
coloc
interact
directli
interact
decreas
ubiquitin
proteasom
degrad
chaperon
protect
protein
synthesi
initi
process
enhanc
cell
surviv
cell
stress
induc
castrat
chemotherapi
forc
overexpress
induc
resist
androgenwithdraw
docetaxel
treatment
prostat
lncap
cell
line
vitro
aggreg
find
identifi
modul
establish
potenti
mechan
cell
death
androgen
ablat
chemotherapi
accordingli
target
interact
may
serv
therapeut
option
advanc
pc
human
varieti
tumor
type
previous
describ
exhibit
elev
level
includ
advanc
pc
overexpress
translat
initi
involv
malign
transform
chemoresist
vitro
vivo
thu
repres
import
target
cancer
therapi
mani
approach
year
use
tri
inhibit
function
particularli
use
small
molecul
inhibitor
disrupt
interact
use
cap
analog
directli
target
capbind
site
aso
proven
effici
reduc
express
level
test
mani
clinic
trial
prostat
cancer
patient
aim
disrupt
mechan
involv
castrationresist
progress
prostat
cancer
toward
goal
work
identif
interact
site
order
find
potenti
inhibitor
interact
perform
screen
compound
bret
experi
found
one
candid
deriv
phenazin
compound
dna
interc
agent
inhibit
interact
lead
cell
viabil
inhibit
increas
apoptosi
castrationresist
prostat
cancer
cell
delet
mutant
use
determin
region
heat
shock
protein
interact
figur
result
show
interact
mutant
proteinprotein
interact
inhibit
truncat
ctermin
part
mutant
figur
evalu
interact
involv
chemoresist
cell
transfect
delet
mutant
prior
docetaxel
treatment
combin
androgen
depriv
rat
colon
carcinoma
cancer
cell
line
reg
cell
endogen
express
analysi
cell
viabil
show
cell
sensit
chemotherapi
docetaxel
androgen
withdraw
serum
free
media
increas
presenc
mutant
figur
thu
data
confirm
loss
interact
via
truncat
ctermin
region
restor
chemo
hormon
sensit
cancer
cell
evalu
effect
phosphoryl
interact
mutant
correspond
constitut
unphosphoryl
phosphoryl
form
use
figur
result
show
interact
phosphoryl
form
mutant
similar
one
observ
wt
protein
partial
inhibit
interact
found
unphosphoryl
form
mutant
figur
show
phosphoryl
regul
interact
understand
implic
phosphoryl
cell
drug
resist
transfect
cell
treat
docetaxel
serum
free
media
analysi
cell
viabil
show
unphosphoryl
mutant
restor
sensit
cell
death
driven
docetaxel
androgen
withdraw
effect
cell
viabil
observ
case
constitut
phosphoryl
mutant
mimic
figur
result
obtain
lncap
prostat
cancer
model
data
shown
result
demonstr
phosphoryl
partli
regul
interact
confirm
loss
interact
induc
treatmentsensit
ration
result
molecular
level
first
extens
molecular
dynam
md
run
carri
wt
complex
figur
retriev
interprotein
bind
free
energi
valu
kcalmol
tabl
reveal
good
affin
two
polypeptid
agreement
experiment
evid
perresidu
bind
enthalpi
re
analysi
allow
determin
residu
mainli
involv
interact
figur
accordingli
found
wt
bind
initi
factor
mainli
exploit
initi
residu
domain
wdpf
wtryptophan
daspart
acid
pprolin
fphenylalanin
final
residu
flexibl
domain
ctermin
region
last
provid
favor
contribut
bind
two
time
larger
afford
amino
acid
ntermin
part
figur
comput
approach
appli
bind
three
truncat
form
ie
protein
expect
valu
truncat
form
less
favor
compar
wt
protein
tabl
yet
specif
trend
could
clearli
discern
inde
presenc
ctermin
part
still
endow
mutant
good
bind
capabl
induc
small
decreas
bind
affin
respect
wt
kcalmol
hand
isoform
still
abl
maintain
minim
affin
wdpf
residu
howev
absenc
ctermin
region
lead
strong
reduct
interact
surfac
figur
turn
reflect
loss
almost
kcalmol
tabl
lastli
presenc
sole
wdpf
domain
mutant
form
allow
format
network
weak
interact
reflect
plummet
kcalmol
relev
valu
tabl
figur
aggreg
silico
result
confirm
import
interact
involv
bind
protein
initi
factor
provid
ctermin
part
strictli
agreement
coimmunoprecipit
experi
visual
interact
search
eventu
inhibitor
interact
bret
assay
live
cell
cell
extract
perform
use
differ
combin
construct
figur
yfp
yellow
fluoresc
protein
luc
luciferas
bound
either
n
ctermin
region
protein
see
si
confirm
interact
fusion
protein
fusion
protein
live
cell
figur
bret
signal
coupl
protein
obtain
previous
describ
bret
experi
live
cell
figur
next
identifi
potenti
inhibitor
interact
screen
chemic
compound
cell
extract
carri
perform
screen
use
phenazin
deriv
previous
shown
antitumor
activ
pancreat
prostat
cell
line
structur
similar
inhibitor
interact
figur
time
test
compound
report
literatur
inhibitor
interact
order
see
also
inhibit
interact
figur
compound
test
reveal
dosedepend
inhibitori
effect
interact
figur
phenazin
deriv
well
show
signific
inhibit
shown
see
inhibit
specif
due
interact
rather
nonspecif
protein
degrad
test
irrelev
coupl
protein
result
show
inhibit
interact
support
specif
interact
inhibit
figur
screen
allow
us
highlight
first
compound
potenti
inhibit
interact
confirm
fact
phenazinederiv
inhibit
endogen
interact
cell
perform
immunofluoresc
coimmunoprecipit
experi
result
perform
androgenindepend
prostat
cancer
cell
demonstr
locat
cell
cytoplasm
figur
prevent
interact
figur
without
effect
protein
express
level
figur
bret
assay
establish
compound
inhibit
interact
wt
protein
initi
factor
reason
disrupt
could
caus
bind
initi
factor
subsequ
alter
protein
structur
final
effect
could
ultim
translat
modif
interact
surfac
wt
turn
impli
impair
correspond
energi
bind
verifi
hypothesi
plausibl
bind
caviti
region
protein
belong
interact
surfac
complex
identifi
figur
md
simul
result
complex
carri
mmpbsa
result
yield
good
bind
affin
molecul
protein
kcalmol
agreement
inhibitor
activ
demonstr
bret
assay
specif
bind
mode
analyz
perresidu
decomposit
enthalp
compon
free
energi
bind
re
collect
data
figur
reveal
complex
stabil
three
main
interact
type
network
stabil
hydrophob
interact
involv
two
alkyl
chain
ii
two
persist
polar
interact
anchor
amin
substitu
protein
iii
weak
hydrogen
bond
engag
nitrogen
atom
phenazin
ring
figur
stabl
complex
also
import
consequ
protein
structur
viewpoint
reflect
overal
arrang
structur
specif
region
involv
proteinprotein
interfac
figur
corrobor
assumpt
comput
approach
appli
wt
complex
inhibitori
effect
quantifi
actual
presenc
ligand
lead
drastic
reduct
bind
interact
wt
initi
factor
loss
kcalmol
correspond
calcul
free
energi
bind
figur
titrat
protein
solut
isotherm
titrat
calorimetri
itc
confirm
bind
result
obtain
comput
procedur
figur
inde
affin
nanomolar
rang
nm
moreov
correspond
valu
kcalmol
obtain
fundament
relationship
rt
lnkd
outstand
agreement
calcul
mmpbsa
comput
approach
kcalmol
see
thermodynam
viewpoint
process
larg
enthalpi
driven
kcalmol
entropi
variat
slightli
disfavor
bind
kcalmol
final
molar
ratio
identifi
number
ligand
per
protein
n
close
n
definit
support
stoichiometri
complex
order
evalu
effect
interact
inhibit
prostat
cancer
model
treat
androgenindepend
docetaxelresist
cell
differ
concentr
phenazin
inhibit
interact
decreas
cell
viabil
dosedepend
manner
figur
increas
cell
death
androgenindepend
model
figur
interestingli
deriv
restor
chemosensit
docetaxelresist
induc
cell
figur
encourag
nontox
promis
vitro
result
obtain
compound
vivo
experi
conduct
assess
effect
tumor
growth
figur
show
green
line
significantli
reduc
androgenindepend
tumor
growth
p
compar
pb
treatment
blue
line
kill
tumor
volum
anim
treat
compound
smaller
harvest
pb
treat
group
figur
immunohistochem
studi
analysi
figur
demonstr
prolifer
index
level
compound
treat
group
significantli
lower
control
group
pb
indic
lower
cell
prolifer
tumor
henc
higher
antitumor
activ
molecul
optic
densiti
od
correl
antigen
express
next
measur
found
mean
express
significantli
increas
tumor
treat
pb
compar
tumor
treat
p
figur
result
confirm
efficaci
phenazinederiv
decreas
tumor
proliferationinandrogenindepend
model
develop
crpc
inevit
progress
pc
androgen
ablat
stage
treatment
option
limit
recent
chemotherapeut
agent
docetaxel
repres
treatment
choic
castrat
resist
emerg
prolong
mean
life
span
patient
month
overexpress
antiapoptot
protein
mrna
splice
event
gene
fusion
loss
express
tumor
suppressor
gene
posttranscript
modif
use
mirna
epigenet
alter
hallmark
crpc
numer
cytoprotect
function
involv
cell
migrat
cytoskeleton
architectur
cell
growth
differenti
tumor
progress
despit
promis
clinic
trial
result
inhibitor
apatorsen
longterm
inhibit
surviv
protein
might
accompani
cytotox
effect
due
role
protein
sever
physiolog
process
avoid
problem
altern
therapeut
strategi
consist
use
compound
disrupt
specif
proteinprotein
interact
ppi
partner
mediat
cytoprotect
effect
previou
investig
show
interact
directli
interact
decreas
ubiquitin
proteasom
degrad
chaperon
appear
protect
protein
synthesi
initi
process
enhanc
cell
surviv
cell
stress
induc
castrat
chemotherapi
studi
sought
character
import
facet
interact
first
use
coimmunoprecipit
figur
bret
assay
figur
demonstr
interact
may
involv
ctermin
domain
loss
interact
restor
chemo
hormonesensit
pc
next
determin
phosphoryl
enhanc
interact
figur
final
identifi
character
first
compound
abl
inhibit
interact
figur
evalu
effect
phosphoryl
interact
use
phosphoryl
nonphosphoryl
form
immunoprecipit
show
interact
phosphoryl
form
partial
interact
inhibit
nonphosphoryl
form
figur
detect
structur
function
studi
indic
chaperon
properti
correl
abil
protein
form
larg
oligom
mediat
nonphosphoryl
form
hand
tripl
mutant
phosphoryl
mimic
capabl
form
tetram
less
chaperon
activ
wild
type
protein
zoubeidi
et
al
shown
phosphoryl
displac
androgen
receptor
thu
take
place
allow
transport
receptor
nucleu
subsequ
activ
transcript
target
gene
interact
avoid
bind
promot
ubiquitin
degrad
proteasom
work
indic
similar
role
protect
degrad
ubiquitinproteasom
system
allow
mainten
protein
synthesi
hypothesi
sort
function
protein
reinforc
fact
seem
select
respect
target
degrad
exampl
act
action
cell
cycl
protein
cyclin
e
anoth
observ
drawn
studi
ntermin
domain
express
seem
interact
strongli
cter
part
mutant
loss
interact
mutant
involv
least
part
increas
treatmentsensit
cell
figur
thu
differ
portion
molecul
may
respons
mediat
respons
differ
stimuli
exampl
ctermin
domain
may
larg
respons
respons
stress
wherea
ntermin
could
respons
modul
hormon
signal
anoth
studi
indic
ctermin
retain
flexibl
interact
dithiothereitol
suggest
highli
flexibl
ctermin
mammalian
shsp
requir
full
chaperon
activ
shown
ctermin
phosphoryl
act
switch
regul
cochaperon
bind
indic
cancer
cell
possess
elev
protein
fold
environ
concert
action
cochaperon
express
chaperon
modif
literatur
data
indic
chaperonelik
activ
small
heat
shock
protein
depend
properti
ctermin
extens
delet
overexpress
cancer
tissu
correl
anticanc
drug
resist
make
promis
molecular
target
drug
develop
present
result
demonstr
compound
dosedepend
inhibitori
effect
interact
figur
bret
assay
accordingli
could
repres
effici
select
new
anticanc
compound
far
phenazin
deriv
abl
inhibit
interact
bret
assay
constitut
effici
methodolog
studi
ppi
nativ
condit
compar
screen
assay
perform
use
solubl
fragment
target
protein
actual
bret
assay
demonstr
capac
compound
disrupt
interact
analog
bret
approach
previous
use
success
order
design
synthet
inhibitor
abl
disrupt
mclbim
interact
ovarian
carcinoma
inhibitor
abil
dissoci
bim
whole
live
cell
acquir
sensit
ovarian
cancer
cell
bclx
increas
cell
death
recent
phenazin
deriv
eg
compound
classifi
anticanc
agent
inde
compound
test
vitro
human
pancreat
cell
line
prove
compound
appear
cytotox
gemcitabin
vivo
result
demonstr
activ
compar
standard
drug
time
lower
concentr
shown
figur
administr
free
compound
moder
retard
tumor
growth
dosag
support
immunohistochem
ihc
analysi
quantif
evalu
tumor
cell
prolifer
figur
reveal
level
compound
treatment
group
much
lower
altern
treatment
group
pb
indic
lower
cell
prolifer
tumor
henc
higher
antitumor
activ
studi
manag
determin
site
interact
two
protein
consid
therapeut
target
pc
inde
consid
protooncogen
overexpress
caus
tumorigen
transform
fibroblast
overexpress
caus
resist
tumor
cell
treatment
rational
target
interact
longterm
inhibit
two
protein
separ
may
toxic
cell
inde
multifunct
protein
involv
sever
biolog
process
long
inhibit
lead
deregul
malfunct
translat
initi
mechan
disrupt
process
cell
transform
work
also
allow
better
character
interact
demonstr
specif
inhibit
interact
phenazinederiv
inde
treatment
cell
inhibit
prolifer
androgenindepend
cell
vitro
vivo
restor
docetaxel
sensit
docetaxelresist
pc
cell
conclus
phenazinederiv
could
repres
interest
therapeut
option
restor
hormon
chemosensit
late
stage
diseas
therapeut
altern
current
work
improv
solubl
biodisponibilti
phenazin
compound
use
nucleolipid
nanovector
order
test
clinic
trial
human
androgenindepend
cell
line
american
type
cultur
collect
usa
maintain
dmem
media
invitrogen
franc
supplement
fetal
bovin
serum
fb
rat
colon
carcinoma
cancer
cell
line
reg
provid
dr
carmen
garrido
inserm
dijon
franc
maintain
medium
invitrogen
supplement
fb
human
embryon
kidney
cell
line
american
type
cultur
collect
usa
maintain
dulbecco
modifi
eagl
medium
invitrogen
supplement
fb
cell
line
cultiv
resist
cell
line
kindli
provid
dr
martin
gleav
vancouv
prostat
cancer
center
maintain
cultur
previous
describ
cell
transfect
fugen
hd
transfect
reagent
promega
franc
day
seed
dna
delet
mutant
phosphoryl
mutant
plasmid
see
mutant
plasmid
bret
plasmid
see
bret
section
previous
describ
clear
lysat
adjust
protein
concentr
pierc
bca
protein
assay
thermo
fisher
scientif
franc
use
immunoprecipit
rabbit
antibodi
cell
signal
ozym
franc
previous
publish
precis
immun
complex
precipit
hour
incub
trueblot
antirabbit
immunoglobulin
bead
ebiosci
pari
franc
complex
resuspend
protein
sampl
buffer
biorad
boil
minut
western
blot
describ
use
rabbit
trueblot
antirabbit
igg
secondari
antibodi
ebiosci
reveal
western
blot
western
blot
wb
perform
mous
antipolyhistidin
antibodi
sigmaaldrich
usa
rabbit
antibodi
cell
signal
ozym
antimous
igg
hrp
conjug
antibodi
promega
franc
antirabbit
trueblot
igg
hrp
conjug
antibodi
antimous
trueblot
igg
hrp
conjug
antibodi
ebiosci
antirabbit
igg
hrp
conjug
antibodi
santa
cruz
biotechnolog
germani
rabbit
antibodi
assay
design
franceload
level
normal
use
mous
antivinculin
antibodi
sigmaaldrich
reblot
plu
mild
solut
millipor
franc
use
membran
strip
min
rt
cell
transient
transfect
day
seed
delet
phosphoryl
mutant
plasmid
describ
treat
transfect
cell
treat
docetaxel
sanofiaventi
franc
serumfre
media
mimick
androgen
withdraw
vitro
cell
viabil
assess
use
tetrazolium
bromid
mtt
assay
reg
cell
previous
describ
assay
perform
triplic
statist
analysi
perform
use
graphpad
prism
program
graphpad
softwar
san
diego
usa
data
mean
sem
signific
differ
assess
twotail
student
ttest
p
consid
signific
p
p
cell
seed
plate
contain
cover
glass
treat
fb
densiti
cellswel
later
cell
treat
compound
dmso
indic
treatment
cell
wash
fix
formaldehyd
thermo
fisher
scientif
franc
rt
extens
wash
perform
mount
cover
glass
glass
slide
use
prolong
gold
antifad
reagent
dapi
life
technolog
franc
glass
slide
allow
dri
dark
rt
cover
glass
immobil
nail
polish
fluoresc
imag
compound
absorpt
emiss
dapi
absorpt
emiss
captur
zeiss
meta
fluoresc
confoc
microscop
plan
le
pecq
franc
flow
cytometri
propidium
iodidestain
nuclei
perform
describ
previous
briefli
cell
seed
dish
densiti
cellswel
later
cell
treat
compound
indic
dna
content
determin
flow
cytometri
use
lsrii
sorp
becton
dickinson
franc
machin
rate
cell
death
measur
use
flowjo
softwar
tree
star
inc
cell
inocul
flank
region
athym
male
mice
nsg
tumor
measur
weekli
volum
calcul
formula
tumor
reach
mice
randomli
select
treatment
pb
control
alon
experiment
group
consist
control
mice
mice
treat
phenazin
test
highest
solubl
inject
last
week
two
inject
per
week
data
point
express
averag
tumor
volum
level
paraffin
section
tumor
dri
overnight
room
temperatur
antibodi
stain
slide
first
incub
h
incub
min
envis
flex
target
retriev
solut
low
ph
ph
dako
uk
ltd
follow
pretreat
epitop
retriev
solut
contain
deterg
dako
uk
ltd
min
room
temperatur
unmask
bind
epitop
block
endogen
peroxidas
activ
dako
envis
flex
peroxidas
block
reagent
readi
use
dako
uk
ltd
min
slide
wash
thoroughli
wash
buffer
flex
dako
uk
ltd
one
wash
flex
buffer
slide
incub
flex
monoclon
mous
antihuman
clone
dako
uk
ltd
h
room
temperatur
two
wash
flex
buffer
dako
envis
flexhrp
dako
uk
ltd
ad
min
room
temperatur
two
final
wash
flex
buffer
stain
visual
ad
diaminobenzidin
dako
uk
ltd
min
room
temperatur
slide
wash
well
flex
buffer
counterstain
envis
flex
hematoxilin
dako
uk
ltd
min
wash
flex
buffer
water
dehydr
clear
mount
aqueou
mount
media
leica
autostain
jung
xl
posit
neg
control
perform
batch
slide
compar
quantif
immunolabel
tissu
type
perform
use
antibodi
tumor
section
stain
intens
optic
densiti
per
unit
surfac
area
measur
automat
imag
analyz
motic
imag
advanc
version
motic
china
group
co
china
light
microscop
field
per
section
use
object
delimit
surfac
area
carri
manual
use
mous
imag
analyz
posit
immunostain
section
one
neg
control
section
follow
seri
consecut
section
also
use
optic
densiti
control
section
taken
away
stain
section
averag
valu
obtain
automat
imag
analyz
tumor
mean
sem
tumor
pb
calcul
number
section
examin
determin
success
approach
obtain
minimum
number
requir
reach
lowest
sem
statist
signific
mean
tumor
group
sampl
assess
fisher
exact
test
oneway
anova
test
graphpad
prisma
